8-K: Seelos Therapeutics Secures $1.1 Million in Registered Direct Offering
Capital Raise Announcement
Seelos Therapeutics, Inc. has entered into a securities purchase agreement to raise approximately $1.1 million through a registered direct offering and concurrent private placement.
Summary
- Seelos Therapeutics, Inc. has entered into a securities purchase agreement with institutional investors to sell 380,968 shares of common stock and pre-funded warrants for up to 81,239 shares in a registered direct offering.
- In a concurrent private placement, the company will also issue unregistered warrants to purchase up to 924,414 shares of common stock.
- The combined purchase price for one share and accompanying warrants is $2.46, while the price for one pre-funded warrant and accompanying warrants is $2.459.
- Pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately.
- Common warrants have an exercise price of $2.21 per share, are exercisable immediately, and expire five years after issuance.
- The offering closed on May 21, 2024, with gross proceeds of approximately $1.1 million before deducting fees and expenses.
- The company intends to use the net proceeds to repay $0.26 million of principal and accrued interest on a convertible promissory note and for general corporate purposes, including advancing product development.
Sentiment
Score: 4
Explanation: The document indicates a necessary capital raise, which is dilutive to existing shareholders and suggests financial challenges. While the company is securing funds, the terms and use of proceeds are not overwhelmingly positive.
Positives
- The company successfully raised capital through a direct offering and private placement.
- The funds will be used to reduce debt and support the development of product candidates.
- The pre-funded warrants allow for immediate exercise at a nominal price.
- The offering includes both registered and unregistered securities, providing flexibility for investors.
Negatives
- The offering involves the issuance of a significant number of new shares and warrants, which could dilute existing shareholders.
- The company is using a portion of the proceeds to repay debt, indicating potential financial challenges.
- The warrants have a relatively low exercise price, which could lead to further dilution if exercised.
Risks
- The company's ability to achieve its development goals is dependent on the successful use of the net proceeds.
- The exercise of warrants could lead to further dilution of existing shareholders.
- The company is subject to market conditions and other risks detailed in its periodic reports.
- The company is required to file a registration statement for the resale of the common warrant shares by June 15, 2024.
Future Outlook
The company intends to use the net proceeds from the offering for general corporate purposes and to advance the development of its product candidates, as well as to make periodic principal and interest payments under, or to repay a portion of, the convertible promissory note.
Industry Context
This capital raise is typical for a biotechnology company in the development stage, as they often require significant funding to advance their research and clinical trials. The use of a registered direct offering and private placement is a common strategy to secure funding from institutional investors.
Comparison to Industry Standards
- The use of registered direct offerings and private placements is a common method for small-cap biotech companies to raise capital, similar to companies like Athersys and BioLineRx.
- The terms of the warrants, including the exercise price and expiration date, are within the typical range for such financings in the biotech sector.
- The 7% placement agent fee is also within the standard range for similar transactions.
- The company's decision to use a portion of the proceeds to repay debt is not uncommon for companies with existing financial obligations, similar to companies like Ocugen and Cassava Sciences.
Stakeholder Impact
- Shareholders will experience dilution due to the issuance of new shares and warrants.
- Creditors will benefit from the repayment of a portion of the company's debt.
- Employees may benefit from the continued operation and development of the company.
- Customers may benefit from the advancement of the company's product candidates.
Next Steps
- The company will file a registration statement on Form S-1 for the resale of the common warrant shares by June 15, 2024.
- The company will use the net proceeds for debt repayment and general corporate purposes, including advancing product development.
Key Dates
| Date | Description |
|---|---|
| 2021-11-23 | Date of original Convertible Promissory Note No. 1 issued to Lind Global Asset Management V, LLC. |
| 2021-12-10 | Date of amendment to Convertible Promissory Note No. 1. |
| 2023-02-08 | Date of amendment to Convertible Promissory Note No. 1. |
| 2023-05-19 | Date of amendment to Convertible Promissory Note No. 1. |
| 2023-09-30 | Date of amendment to Convertible Promissory Note No. 1. |
| 2023-12-18 | Date of filing of the shelf registration statement on Form S-3. |
| 2023-12-27 | Date the shelf registration statement on Form S-3 was declared effective. |
| 2024-03-27 | Date of amendment to Convertible Promissory Note No. 1. |
| 2024-05-01 | Date of amendment to Convertible Promissory Note No. 1. |
| 2024-05-16 | Date of the securities purchase agreement and placement agency agreement. |
| 2024-05-21 | Closing date of the offering. |
| 2024-06-15 | Deadline for filing a registration statement on Form S-1 for the resale of common warrant shares. |
Keywords
registered direct offering, private placement, securities purchase agreement, common stock, pre-funded warrants, common warrants, capital raise, dilution, debt repayment, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.